Skip to main content

Quest Completes Athena Deal

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today announced the completion of its acquisition of Athena Diagnostics from Thermo Fisher Scientific.

The $740 million deal was announced in late February.

Athena will continue to operate under its own name as an independent business within Quest, and its clinical laboratory in Worcester, Mass., is now the center of excellence in neurology diagnostics for Quest, the Madison, N.J.-based diagnostics testing firm said.

"With this acquisition, Quest Diagnostics has clearly established the leading position in the neurology diagnostics market, "Surya Mohapatra, chairman and CEO of Quest, said in a statement.

Athena generated about $110 million in revenues in 2010 and was part of Thermo Fisher's specialty diagnostics business within its Analytical Technologies segment.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.